SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-232208
Filing Date
2021-08-02
Accepted
2021-08-02 07:05:55
Documents
14
Period of Report
2021-07-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d209269d8k.htm   iXBRL 8-K 23912
2 EX-99.1 d209269dex991.htm EX-99.1 10061
6 GRAPHIC g209269g14q94.jpg GRAPHIC 2804
  Complete submission text file 0001193125-21-232208.txt   168581

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gthx-20210727.xsd EX-101.SCH 2908
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gthx-20210727_lab.xml EX-101.LAB 18906
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gthx-20210727_pre.xml EX-101.PRE 11873
7 EXTRACTED XBRL INSTANCE DOCUMENT d209269d8k_htm.xml XML 3478
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 211134717
SIC: 2834 Pharmaceutical Preparations